Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines

albicans ribosomes as a prophylactic vaccine candidiasis in mice. Vac-
cine. 1997;15:220–4.
109. Masek J, Bartheldyova E, Turanek-Knotigova P, Skrabalova M, Korvasova 
Z, Plockova J, Koudelka S, Skodova P, Kulich P, Krupka M, et al. Metal-
lochelating liposomes with associated lipophilised norAbuMDP as 
biocompatible platform for construction of vaccines with recombi-
nant His-tagged antigens: preparation, structural study and immune 
response towards rHsp90. J Control Release. 2011;151:193–201.
110. Knotigova PT, Zyka D, Masek J, Kovalova A, Krupka M, Bartheldyova E, 
Kulich P, Koudelka S, Lukac R, Kauerova Z, et al. Molecular adjuvants 
based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP 
formulated in nanoliposomes: stimulation of innate and adaptive 
immunity. Pharm Res. 2015;32:1186–99.
111. Carneiro C, Correia A, Collins T, Vilanova M, Pais C, Gomes AC, Oliveira 
ME, Sampaio P. DODAB:monoolein liposomes containing Candida 
albicans cell wall surface proteins: a novel adjuvant and delivery system. 
Eur J Pharm Biopharm. 2015;89:190–200.
112. Carneiro C, Correia A, Lima T, Vilanova M, Pais C, Gomes AC, Real Oliveira 
MECD, Sampaio P. Protective effect of antigen delivery using mono-
olein-based liposomes in experimental hematogenously disseminated 
candidiasis. Acta Biomater. 2016;39:133–45.
113. Postma NS, Hermsen CC, Zuidema J, Eling WMC. Plasmodium vinckei: 
optimization of desferrioxamine B delivery in the treatment of murine 
malaria. Exp Parasitol. 1998;89:323–30.
114. Stewart VA, McGrath SM, Walsh DS, Davis S, Hess AS, Ware LA, Kester 
KE, Cummings JF, Burge JR, Voss G, et al. Pre-clinical evaluation of new 
adjuvant formulations to improve the immunogenicity of the malaria 
vaccine RTS, S/AS02A. Vaccine. 2006;24:6483–92.
115. Ready PD. Epidemiology of visceral leishmaniasis. Clin Epidemiol. 
2014;6:147–54.
116. Bhowmick S, Ravindran R, Ali N. Leishmanial antigens in liposomes 
promote protective immunity and provide immunotherapy 
against visceral leishmaniasis via polarized Th1 response. Vaccine. 
2007;25:6544–56.
117. Banerjee A, De M, Ali N. Complete cure of experimental visceral 
leishmaniasis with amphotericin B in stearylamine-bearing cationic 
liposomes involves down-regulation of IL-10 and favorable T cell 
responses. J Immunol. 2008;181:1386–98.
118. Banerjee A, Roychoudhury J, Ali N. Stearylamine-bearing cationic 
liposomes kill Leishmania parasites through surface exposed negatively 
charged phosphatidylserine. J Antimicrob Chemother. 2008;61:103–10.
119. Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleesschauwer B, 
Dopfer D, Fazil A, Fischer-Walker CL, Hald T, et al. World Health Organiza-
tion estimates of the global and regional disease burden of 22 food-
borne bacterial, protozoal, and viral diseases, 2010: a data synthesis. 
Plos Med. 2015;12:21.
120. World Health Organization. Global tuberculosis report 2016. Geneva: 
World Health Organization; 2016.
121. Houben R, Dodd PJ. The global burden of latent tuberculosis infection: 
a re-estimation using mathematical modelling. Plos Med. 2016;13:13.
122. Tsuruta LR, Quintilio W, Costa MHB, CarmonaRibeiro AM. Interactions 
between cationic liposomes and an antigenic protein: the physical 
chemistry of the immunoadjuvant action. J Lipid Res. 1997;38:2003–11.
123. Snippe H, Belder M, Willers JMN. Dimethyl dioctadecyl ammonium 
bromide as adjuvant for delayed-hypersensitivity in mice. Immunology. 
1977;33:931–6.
124. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination 
of the cationic surfactant dimethyl dioctadecyl ammonium bromide 
and synthetic mycobacterial cord factor as an efficient adjuvant for 
tuberculosis subunit vaccines. Infect Immun. 2004;72:1608–17.
125. Rosenkrands I, Agger EM, Olsen AW, Korsholm KS, Andersen CS, Jensen 
KT, Andersen P. Cationic liposomes containing mycobacterial lipids: a 
new powerful Th1 adjuvant system. Infect Immun. 2005;73:5817–26.
126. Liu X, Da Z, Wang Y, Niu H, Li R, Yu H, He S, Guo M, Wang Y, Luo Y, et al. 
A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis 
subunit vaccine well to induce cell-mediated immunity and high 
protective efficacy in mice. Vaccine. 2016;34:1370–8.
127. Hamborg M, Rose F, Jorgensen L, Bjorklund K, Pedersen HB, Christensen 
D, Foged C. Elucidating the mechanisms of protein antigen adsorption 
to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, 
fluidity and antigen-to-lipid ratio. Biochim Biophys Acta Biomembr. 
2014;1838:2001–10.
128. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard 
C, Werninghaus K, Kirschning C, Lang R, Christensen D, et al. Cationic 
liposomes formulated with synthetic mycobacterial cordfactor (CAF01): 
a versatile adjuvant for vaccines with different immunological require-
ments. PLoS ONE. 2008;3:10.
129. Derrick SC, Yabe I, Morris S, Cowley S. Induction of unconventional T 
cells by a mutant Mycobacterium bovis BCG strain formulated in cationic 
liposomes correlates with protection against Mycobacterium tubercu-
losis infections of immunocompromised mice. Clin Vaccine Immunol. 
2016;23:638–47.
130. Boissier F, Bardou F, Guillet VR, Uttenweiler-Joseph S, Daffe M, Quemard 
A, Mourey L. Further insight into S-adenosylmethionine-dependent 
methyltransferases—structural characterization of Hma, an enzyme 

---

Page 23 of 23
De Serrano and Burkhart  J Nanobiotechnol (2017) 15:83